Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 295.17M P/E - EPS this Y 11.40% Ern Qtrly Grth -
Income - Forward P/E 23.00 EPS next Y 12.90% 50D Avg Chg 9.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -4.00%
Dividend N/A Price/Book 30.26 EPS next 5Y - 52W High Chg -46.00%
Recommedations 1.80 Quick Ratio - Shares Outstanding 226.14M 52W Low Chg 68.00%
Insider Own 45.78% ROA - Shares Float - Beta -
Inst Own 9.50% ROE - Shares Shorted/Prior 15.96M/16.40M Price 1.15
Gross Margin - Profit Margin - Avg. Volume 488,290 Target Price 7.20
Oper. Margin - Earnings Date Feb 13 Volume 213,572 Change -1.71%
About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Outlook Therapeutics, Inc. News
01/19/23 Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence
01/11/23 JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
01/09/23 Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event
01/02/23 Breakeven On The Horizon For Outlook Therapeutics, Inc. (NASDAQ:OTLK)
12/29/22 Outlook Therapeutics® Reports Financial Results for Fiscal Year 2022 and Provides Corporate Update
12/23/22 Outlook Therapeutics® Enters Definitive Agreement for $31.8 Million Unsecured Convertible Promissory Note
12/23/22 Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
12/22/22 Outlook Therapeutics® Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD
12/01/22 Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
11/22/22 Outlook Therapeutics® to Present at the BTIG Ophthalmology Day
11/01/22 Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) top owners are individual investors with 38% stake, while 25% is held by private equity firms
10/28/22 Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
10/05/22 Independent Director Kurt Hilzinger Just Bought 33% More Shares In Outlook Therapeutics, Inc. (NASDAQ:OTLK)
09/27/22 Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD
09/26/22 Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022
09/07/22 Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment Conference
08:39 AM Outlook Therapeutics Shares Pop After Filing US Application For Its Lead Eye Disease Candidate
07:05 AM Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
08/15/22 Outlook Therapeutics Strengthens Board of Directors with Appointment of Julia A. Haller, MD
08/10/22 Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones
OTLK Chatroom

User Image Britboxisback Posted - 2 hours ago

$OTLK I’ve blocked so many fools on here I think only like 5 people see my posts lol

User Image Britboxisback Posted - 2 hours ago

$OTLK 6 1/2 months until FDA approval on a guaranteed multi billion dollar a year drug with 12 years exclusivity, or BO before then. That’s what’s called a win-win scenario. No matter which way it goes, daddy’s gonna get paid.

User Image sta120908 Posted - 12 hours ago


User Image Baberuth1951 Posted - 12 hours ago

$OTLK Two years ago I made a boatload on this and since then it has been a nightmare. Great things were supposed to happen and it all went nowhere. It was supposed to be on the market in months and then..........

User Image Britboxisback Posted - 14 hours ago

$OTLK hope everyone is as excited as I am for the big week since we are most likely going to hear……NOTHING lol.

User Image MisterWizard Posted - 23 hours ago

$OTLK read the Pre 14a. Fools.

User Image ElvisAPresley Posted - 1 day ago

$OTLK wiz…name one successful company that didn’t dilute in their pre rev days? Of course they have to raise money…isn’t that why every co chooses to go public…many want to expand & need funding. So if that’s your entire thesis to bag on bulls…it’s insignificant to the big pic. Most non scared investors here are investing until a BO or rev comes piling in. This entire investment relies on approval…no one cares about necessary fund raising.

User Image samuelbankmanfried Posted - 1 day ago

$OTLK @CartmansConscience I appreciate the recommendation!

User Image cctranscripts Posted - 2 days ago

Other preliminary proxy statements https://www.conferencecalltranscripts.org/summary/?id=11734234 $ONS

User Image MisterWizard Posted - 2 days ago

$OTLK they’ve diluted you cheerleaders by 38 %+ in the last 12 months. Lol. How much more they gonna dilute you? Don’t you recognize any upside you thought you had is being crushed by dilution?

User Image Fireballz Posted - 2 days ago

$OTLK interesting….

User Image GenerallyGentle Posted - 2 days ago

$OTLK I guess we are going to Philly :) Seems to fit a timeline that was whispered in my ear by the Xmas spirit of things to come .....

User Image m6goodarzi Posted - 2 days ago

$OTLK "Properly brought"? Does this mean more probable dilutions OR something else?

User Image fla Posted - 2 days ago

$OTLK [15s. delayed] filed form PRE 14A on January 27, 16:38:15 https://s.flashalert.me/60qH55

User Image MisterWizard Posted - 2 days ago

$OTLK pre 14k you better read it. You got 5635b’d. you gotta vote for a lot of dilution. ( sung to Beatles revolution) So you say you want major dilution well you know we All wanna change the world. Go back and read what Wiz told you about Share count and balance sheet. More dilution to come. Why oh why would you spec this?

User Image blackhorse14 Posted - 2 days ago

$OTLK where’s buyout on here?

User Image blackhorse14 Posted - 2 days ago

$OTLK they said buyout next Tuesday what a joke

User Image samuelbankmanfried Posted - 2 days ago

$OTLK looks to either be unfortunate or it’s a massive power play to the unregistered buyer who is getting a fat haircut 😭😭

User Image tealeafmuncher Posted - 2 days ago

$OTLK ill bet 425 million shares makes sj and his gang ultra bullish too. Another reverse split will make them so bullish theyll turn into centaurs. Absurd

User Image samuelbankmanfried Posted - 2 days ago


User Image fmlfml Posted - 2 days ago

$OTLK Ugh. A product already in use with no RnD necessary and it's going to be close to a half billion to get them to revenue. I so badly hope there's a BO before or after FDA cause I don't want to be here as these guys take this to market. It's been sloppy.

User Image Quantisnow Posted - 2 days ago

$OTLK 📜 SEC Form PRE 14A filed by Outlook Therapeutics Inc. https://quantisnow.com/i/3967799?utm_source=stocktwits This insight appeared 45 seconds early at ⚡ https://quantisnow.com/feed

User Image risenhoover Posted - 2 days ago

$OTLK / Outlook Therapeutics files form PRE 14A https://fintel.io/sf/us/otlk?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

User Image Newsfilter Posted - 2 days ago

$OTLK Form PRE 14A (other preliminary proxy statements) filed with the SEC https://newsfilter.io/a/720e342daf55c06974582dc983835da5

User Image TheRipple Posted - 2 days ago


User Image Britboxisback Posted - 2 days ago

$OTLK yay we are up 2% lol

User Image Britboxisback Posted - 2 days ago

$OTLK see, daddy was right about Tesla. Balls

User Image hankywills Posted - 2 days ago

$OTLK dont worry next tuesday is BO date. Thats what the latest person to block me said. We rich in 5 days buy them lambos, take out loans, buy expensive stuff you got cash bags coming

User Image upNupAlways3 Posted - 3 days ago

$OTLK I guess someone closed their short position after those accumulation days! 70K shares at market close!

User Image MisterWizard Posted - 3 days ago

$OTLK any thoughts on why stock for sale here? Does appear to be a buyer.

Analyst Ratings
BTIG Buy Oct 31, 22
Chardan Capital Buy Sep 13, 22
HC Wainwright & Co. Buy Aug 27, 20
Oppenheimer Outperform Aug 18, 20
HC Wainwright & Co. Buy May 27, 20
Ladenburg Thalmann Buy Sep 11, 19
H.C. Wainwright Buy Jul 18, 19
Oppenheimer Outperform May 16, 19
Ascendiant Capital Buy Nov 25, 20
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Evanson Jeff Chief Commercial Off.. Chief Commercial Officer Jan 20 Sell 1.11 267,000 296,370 745,975 01/24/23
Evanson Jeff Chief Commercial Off.. Chief Commercial Officer Jan 17 Sell 1.26 164,155 206,835 1,012,975 01/19/23
HILZINGER KURT J Director Director Oct 04 Buy 1.26 111,203 140,116 473,117 10/05/22
Dagnon Terry Chief Operating Offi.. Chief Operating Officer Jun 21 Buy 1.05 10,000 10,500 1,173,058 06/23/22
TRENARY C RUSSELL III CEO and President CEO and President Jun 21 Buy 1.06 19,925 21,120 54,925 06/23/22
HILZINGER KURT J Director Director Mar 01 Buy 1.69 27,708 46,827 273,117 03/03/22
HILZINGER KURT J Director Director Feb 24 Buy 1.53 47,160 72,155 245,409 02/28/22
HILZINGER KURT J Director Director Feb 22 Buy 1.47 175,132 257,444 198,249 02/23/22